BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer

  Tubulis announced the appointment of Björn Hock, PhD, as Chief Development Officer to further strengthen its leadership team with a seasoned drug development expert.

  February 16, 2023

   · 

  3 min read
• Biotech Bay

  IDEAYA Biosciences to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

  IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in Citi’s 2023 Virtual Oncology Leadership Summit.

  February 16, 2023

   · 

  2 min read
• Business

  Syneos Health Reports Fourth Quarter and Full Year 2022 Results

  Syneos Health, a leading fully integrated biopharmaceutical solutions organization, reported financial results for the three months and year ended December 31, 2022.

  February 16, 2023

   · 

  26 min read
• Pharm Country

  Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

  Immunic, Inc. announced that the company will release its financial results for the fourth quarter and year ended December 31, 2022, including a corporate update, on Thursday, February 23, 2023, before the opening of the U.S. financial markets.

  February 16, 2023

   · 

  4 min read
• Business

  Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

  Sage Therapeutics, Inc. reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

  February 16, 2023

   · 

  22 min read
• Drug Development

  Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

  Pfizer Inc. announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine.

  February 16, 2023

   · 

  9 min read
• Drug Development

  Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

  Applied Therapeutics, Inc. announced positive sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial.

  February 16, 2023

   · 

  9 min read
• Business

  Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

  Alkermes plc reported financial results for the quarter and year ended Dec. 31, 2022 and provided financial expectations for 2023.

  February 16, 2023

   · 

  23 min read
• Genetown

  Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders

  Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders.

  February 16, 2023

   · 

  5 min read
• BioMidwest

  NovAccess Global to Present at World Orphan Drug Congress

  NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-25, 2023, near Washington, DC.

  February 16, 2023

   · 

  6 min read